Alex Tarnava currently moves 40 million doses of hydrogen water tablets a month and recently sold out two production runs of a $6,499 medical gas delivery system. He achieved this massive scale without taking a single cent of venture capital. For health-tech founders and early-stage entrepreneurs, Tarnava’s bootstrapping strategy offers a blueprint for scaling a hardware and supplement business without surrendering control to Silicon Valley's profit-first mandates.
Tarnava is the inventor and patent holder of hydrogen water tablets that utilize elemental magnesium and organic acids to generate hydrogen gas. Unlike traditional methods that struggle with hydrogen's limited solubility, his technology creates extremely small nanobubbles that remain suspended in the liquid. This produces a supersaturated solution with up to eight times the typical concentration. Tarnava argues this higher dose triggers hormesis - a mild stress on mitochondria that activates the body’s natural resilience mechanisms.
Scaling Hydrogen Therapy Without Silicon Valley
His product is now private-labeled by roughly 100 brands, including Gary Brecka, Dr. Gundry, Sports Research, QuickSilver Scientific, and The Wellness Company. Beyond tablets, Tarnava co-invented Inhale H2, a patent-pending system for delivering medical gases and aerosolized drugs. Launched in December, the device quickly sold 1,000 units at a $6,499 MSRP.
Despite growing up below the poverty line, Tarnava refused external funding to protect his core mission. He requires even the few close friends who own shares to sign ethics agreements waiving their rights to shareholder primacy.
A lot of people think if I pull in capital, it helps me achieve my mission, but that’s a trap. You have to give up on your mission. Because now the mission becomes money and it’s empty.
- Alex Tarnava, Founder and Inventor
He argues that under traditional shareholder primacy, executives are legally bound to maximize returns, which often degrades the product. "If you discover an avenue to increase profits, your morals or ethics can’t stop you from that, or you’re going to get sued, and lose your company anyway," Tarnava explained. He noted that many altruistic founders bring in capital only to fight with their board and get ousted when they refuse to pivot a genuinely helpful health product into something innocuous just to widen profit margins.
Driving Honest Capitalism Through Education
Tarnava’s early career in commission-based sales in 2002 - where he earned $35,000 part-time while observing 7% compounding interest and inflation - left him disillusioned with traditional corporate structures. Today, he is using his capital to fund the Wellness Science Initiative, a nonprofit providing free educational modules on critical thinking and foundational science.
The initiative is launching its first Olympiad at the Eudemonia event in West Palm Beach from November 5 to 8. The event expects 8,000 attendees and will feature $70,000 in prizes through live science competitions. By teaching consumers how to evaluate lifestyle interventions, Tarnava believes market demand will naturally force companies to abandon deceptive marketing and adopt honest leadership.
The Defensive Moat of Bootstrapping
Tarnava’s refusal to play the venture capital game highlights a critical vulnerability in the modern health-tech sector: the misalignment between clinical efficacy and hyper-growth expectations. When a startup takes VC money, the timeline for returns artificially accelerates. In the wellness industry, this often results in companies slashing active ingredient doses to improve margins or pivoting to subscription models that prioritize recurring revenue over actual patient outcomes.
By bootstrapping, Tarnava essentially built a defensive moat around his intellectual property. His ability to mandate ethics agreements that explicitly waive shareholder primacy is a legal anomaly in corporate structuring, but it is exactly what allows him to maintain an eight-times higher concentration in his hydrogen solutions. If a traditional board were in charge, that concentration would likely be the first cost-cutting casualty. For future founders, the lesson is clear: capital is a tool, but if the legal structure of that capital demands profit above all else, the product itself eventually becomes the compromise.
